Please note: this program is subject to change. 

The HTAi Regional Meeting in Kyiv, Ukraine includes a four-day program, with two-hour sessions each day.

Jump to Workshops

Panels

Welcome Speeches

Date: September 8, 2020
Time:
14:00 – 14:15 CET

Minister of Health of Ukraine, Ukraine
Iñaki Gutierrez-Ibarluzea, HTAi President, Spain
Sophie Söderholm Werkö, INAHTA President, Sweden

Panel One: Towards Universal Health Coverage, unique challenges for emerging countries

The first panel will focus on reforms around the world towards universal health coverage.

Date: September 8, 2020
Time:
14:15 – 16:00 CET

Moderator

Iñaki Gutierrez-Ibarluzea, HTAi President, Spain

Speakers

Deputy Minister, Ministry of Health, Ukraine
Prof. Recep Akdag, Former Minister of Health, Turkey
Adriana Velazquez Berumen, Senior Advisor and Focal Point of Medical Devices WHO, Switzerland

Panel Two: Challenges and opportunities in integrating HTA into successful health reforms

Panel Two will include international examples that have been successful in supporting decision making with improving HTA during health care reforms, but also examples that continue to improve and share some challenges.

Date: September 9, 2020
Time:
14:00 – 16:00 CET

Moderator:

Rabia Kahveci, Senior Technical Advisor Pharmaceutical Policies and Governance, SAFEMed project, USAID, Ukraine

Speakers

Wija Oortwijn, Vice-President, HTAi, Netherlands
Oresta Piniazhko, Director of HTA Department SEC, Ministry of Health, Ukraine
Katrine Fronsdal, Senior Researcher, Norwegian Institute of Public Health, Norway
Alex Kostyuk, Director of Department of Drug Provision and Standardization, Ministry of Health, Kazakhstan
Nabil Seyidov, Head of Department for Health Policy and Reforms, Public Health and Reforms Center, Ministry of Health, Azerbaijan
Marcela Tirdea, Head of Department of Policy Analysis, Monitoring, and Evaluation; Ministry of Health, Moldova

Panel Three: HTA for technology access decisions: how to support development of benefits package and procurement process

The third panel will focus on practical implementation of HTA in specific lines of decision making. These countries usually struggle with how to make evidence-based decisions on the state guaranteed coverage of the technologies where there is a very limited budget. Can HTA help and how?

Date: September 10, 2020
Time:
14:00 – 16:00 CET

Moderator

Hector Castro, Senior Technical Director of Pharmaceutical Economics and Financing at MSH, USA

Speakers

Sarah Garner, Coordinator of Innovation, Access and Use, Essential Medicines and Health Products Department, WHO, Switzerland
Mouna Jameleddine, Head of HTA Department, National Authority for Assessment and Accreditation in Health Care (INEAS), Tunisia
Marcin Czech, Former Deputy Minister of Health, Poland
Debjani (Jani) Mueller, Director HTAi, South Africa

Panel Four: What should stakeholders expect from HTA: can we work together for an integrated, efficient system?

Panel Four will discuss concerns and expectations of the stakeholders from clinical field, patients, industry etc., roles of each, and how engagement can be established.

Date: September 11, 2020
Time: 14:00 – 16:00 CET

Moderator

Alric Ruether, Head of the International Affairs Unit, Institute for Quality and Efficiency in Health Care (IQWiG), Germany

Speakers

Jolanta Bilinska, Former President of the International Alliance of Patient’s Organizations, Poland
Sophie Söderholm Werkö, President of the International Network of Agencies for Health Technology Assessment (INAHTA), Sweden


Workshops

Course One: Introduction to Health Technology Assessment

Facilitators:
Iñaki Gutierrez Ibarluzea, HTAi President, Director of Organizational and Management Innovation, BIOEF, Spain
Jani Mueller, HTAi Director, Senior Researcher, CMeRC South Africa

About the course:

HTAi experts will conduct this introductory course on HTA. The primary focus will be those who are new to this field. However, it will also serve as a refresher for those with prior knowledge on the topic. The course will cover essentials of HTA such as (a) definition and purpose of HTA (b) the role it plays in policy-making and evidence-based decision-making (c) timing of HTA (d) properties assessed (e) different type of HTA products (f) overview of methods in HTA (g) resources needed in HTA (e) evidence needed for HTA.

This will be an interactive session. We will use examples and case studies to align theory with practice of HTA. There will be time for questions and answers and sharing of experiences. Furthermore, the course will cover essentials of HTA, the skill set needed for HTA and different HTA product types to support decision- and policy-making for a given technology or service. It is targeted towards professionals in the health care sector, policy and decision-makers, manufacturers, and any potential HTA user who is new to HTA.

About the facilitators:

Iñaki Gutierrez Ibarluzea
Iñaki is the Director of Organizational and Management Innovation, BIOEF in Spain and the current President of HTAi. He is the coordinator of the early warning and alert system on new and emerging health technologies of Osteba, Basque Office for HTA. Iñaki is the co-chair of the HTAi IG on Disinvestment and Early Awareness, and a member of the information resources IG of HTAi and the liaison person of the Public Health and Nutrition IG.

He was a member of the Board of Directors (2010-2012) and Secretary of the International Society HTAi (2012-2014). He is currently the Vice Chair of EuroScan International Network for the identification and evaluation of new and emerging health technologies. Iñaki is also an associated professor in the School of Nursing of Osakidetza Basque Health Service and works with the University of the Basque Country and the Open University of Catalonia.

He has collaborated with the Spanish Ministry of Industry and the Spanish Observatory for Prospective Technological Studies and is a member and coordinator of the Task Force for Genomics and Public Health. Recently, he has collaborated with WHO-Europe as expert advisor and evaluator on the program of Medical Devices for Countries with limited resources. Iñaki has been advising different HTA initiatives in Argentina, Brazil, Colombia, Costa Rica, Mexico, South Africa, Tunisia, Israel, the Horizon Scanning initiative of EEUU and Italy, WHO-EMRO region, WHO health technologies unit and is member of the HTA glossary committee.

Jani Mueller
Jani is a Senior Researcher at Charlotte Maxeke Medical Research Cluster (CMeRC) in Johannesburg and holds a faculty position with University of Pretoria in South Africa. She has been recently elected as the Director of the Health Technology Assessment International Society (HTAi).

She continues to focus her effort on promotion, collaboration and raising awareness of sustainable HTA development and implementation. She is a founding member of South African HTA Society (SAHTAS), was a director on the INAHTA Board during 2013-2019, and is currently the chair of the HTAi Interest Group on Developing Countries. She has served on the International Scientific Program Committee of HTAi’s Annual Meeting over the years and more recently is an Associate Editor of the Journal of Technology Assessment in Health Care, IJTAHC. Furthermore, she is a Board member of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) South Africa Chapter.

Jani nurtures a keen interest in building competencies and education and training in HTA, especially in emerging settings. Her research focuses on advancing the methods used in the area of medical device assessment to enhance its usefulness in the context of real-world decision-making, involving a life-cycle approach towards assessment. She has published and co-authored a number of articles, contributed to book chapters and presented her research findings to an array of scientific audiences.

Course Two: Health Technology Assessment of Medical Devices

Facilitators:
Adriana Velazquez Berumen, Senior Advisor and Focal Point of Medical Devices at WHO, Switzerland
Rabia Kahveci, HTAi Director, Senior Technical Advisor on Pharmaceutical Policies and Governance, SAFEMed project, Ukraine

About the course:

This short course will be conducted by WHO and HTAi experts with the aim to provide up-to-date information on use of HTA in the field of medical devices. International technical experts will provide insights into HTA, provide general understanding of HTA and its role in access and use of medical devices. Short overview of the methods and tools in this field will be presented, the specific requirements associated with medical devices will be included.

It is targeted at professionals of competent authorities, public institutions, and manufacturers as well as the end users of medical devices. The attendees should be experts who are involved in the selection, assessment, pricing, reimbursement, or procurement of medical devices; medical device manufacturers; or end users of the devices such as patients and physicians.  The interactive format will allow exchange of information, sharing of experiences and capacity-building in HTA for MDs.

About the facilitators:

Adriana Velazquez Berumen
Adriana Velázquez Berumen is the Senior Advisor and Focal Point for Medical Devices, within the Essential Medicines and Health Products department, at World Health Organization (WHO), Geneva. She was previously the Coordinator of Diagnostic Imaging and Medical Devices within the Essential Health Technology Department of WHO. She is responsible for the development of 10 WHO books and publications on medical devices, and 8 books of the medical devices technical series, including development of policies, assessment, donations, procurement, inventories and maintenance. She was responsible of the implementation of the Global Initiative on Health Technologies (GIHT), supported by a grant from the B&M Gates Foundation, and coordinated the First Global survey on medical devices and call for innovative technologies for global health concerns and compilation of a network of health technology focal points in the Member States for further intercommunication and knowledge sharing. Previously she acted as health technology consultant at PAHO/WHO, and was a Founding Director General of the National Center for Health technology Excellence (CENETEC) for the Ministry of Health in Mexico. During her carrier Dr. Adriana was awarded with several awards and held chairing positions in the societies in the field of medical physics and biomedical engineering.

Rabia Kahveci
Rabia is Senior Technical Advisor for Pharmaceutical Policy and Governance of SAFEMed, Ukraine. While working full time, Dr. Rabia continues to remain as one of the Directors of International Health Technology Assessment Society (HTAi), the past-Chair and steering committee member of HTAi Developing Countries Interest Group with members in over 50 countries, Chair of the HTAi Medical Devices Interest Group and the Chair of Eurasian HTA Initiative with institutional members from 9 countries. Prior to her position in SAFEMed, she was the Director of a Hospital-based HTA Center in Turkey that covered HTA, innovation for medical devices and real-world evidence. In Turkey, she also served as a member of the Pharmaceuticals Reimbursement Committee of the Turkish Social Security Institution during transition to universal health coverage and was one of the co-authors of the reimbursement guidelines; the National Clinical Quality Coordinator of the Turkish MoH with the coordinating task of all activities around HTA, clinical guidelines and clinical quality; and the President of Turkish Evidence-Based Medicine Society. She is a professor of family medicine by background with additional trainings in Italy, Spain, Canada, and the USA. She is recognized as an editor of eight books and the author of over 150 articles.

Course Three: Principles of Pharmaceutical Pricing Policies

Facilitator:
Zoltán Kaló, Professor of Health Economics, Center for Health Technology Assessment, Semmelweis University; Syreon Research Institute, Budapest, Hungary

About the course:

Fairness of pharmaceutical pricing is a heavily-debated political and health policy theme all over the world. The course will cover definitions and taxonomies of pharmaceutical pricing policies. Concepts and applicability of key pricing methods for different types of pharmaceuticals – from multisource generic medicines to orphan drugs – will be discussed, including 1) cost plus pricing, 2) internal price referencing, 3) external price referencing, and 4) value-based pricing related to either narrow or extended value frameworks.

The complexity of pharmaceutical pricing is amplified by the fact that on-patent medicines are usually marketed in multiple indications for potentially different target populations in multiple countries. Consequently, incentives created by a national pricing decision in one indication cannot be explored separately from market externalities on patient access in other indications or other countries and implications on the global pharmaceutical innovation cycle.

During the course special attention will be devoted to how policy-makers in developing countries can improve their national pharmaceutical pricing policies by balancing improved patient access to medicines with sustainability of health care financing. The rationale and feasibility of confidential pricing agreements will be discussed.

About the facilitator:

Zoltán Kaló is a Professor of Health Economics at the Center for Health Technology Assessment of Semmelweis University in Budapest, Hungary. Before moving to Semmelweis University in July 2019 he was the founder and co-director of an international master program in Health Policy, Planning and Financing at Eötvös Loránd University (ELTE).

Dr. Kaló is also the founder and leader of Syreon Research Institute, an international research corporation specializing in health policy, health economic modeling and technology assessment.

He has 25 years of international experience in academia and industry, specializing in health systems design, HTA implementation, health economics and outcomes research, patient access and pricing policies of healthcare technologies.

Dr. Kaló serves as a policy advisor to public decision-makers and global health care corporations. He is a Scientific Committee member of the Innovative Medicines Initiative 2 Joint Undertaking (IMI2 JU). He was a Director of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) between 2012-2014, and the Chair of ISPOR Central and Eastern European Network Executive Committee between 2013-2015.